Intanza®: A new intradermal vaccine for seasonal influenza

Expert Review of Vaccines

Volumn 9, Issue 12, 2010, Pages 1399-1409

  Atmar, Robert L ^a   Patel, Shital M ^a   Keitel, Wendy A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

inactivated; influenza; intradermal; microinjection; serum antibody; vaccine

Indexed keywords

ADDIGRIP; FLULAVAL; FLUVAX; HEMAGGLUTININ; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INTANZA; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; SALICYLIC ACID; SIALIDASE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY TITER; AUSTRALIA; CHRONIC RESPIRATORY FAILURE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FACE PAIN; GERIATRIC CARE; GROUPS BY AGE; HEART DISEASE; HEMOGLOBINOPATHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY DISEASE; LONG TERM CARE; LOW DRUG DOSE; METABOLIC DISORDER; MICROINJECTION; MYOCARDITIS; MYOPERICARDITIS; NEURITIS; NONHUMAN; PERICARDITIS; PERITONSILLAR ABSCESS; POPULATION RISK; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; VACCINE PRODUCTION;

AUSTRALIA; EUROPE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; VACCINATION; VACCINES, INACTIVATED;

EID: 78649506567     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.134     Document Type: Review

References (58)

1. Fiore AE, Shay DK, Broder K et al. Prevention and control of infuenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. Recomm. Rep. 59(RR-8), 1-62 (2010).
2. Couch RB, Kasel JA, Glezen WP et al. Infuenza: its control in persons and populations. J. Infect. Dis. 153(3), 431-440 (1986).
3. Glezen WP, Couch RB. Interpandemic infuenza in the Houston area, 1974-76. N. Engl. J. Med. 298(11), 587-592 (1978).
4. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal infuenza in the US: measuring disease burden and costs. Vaccine 25(27), 5086-5096 (2007).
5. Thompson WW, Shay DK, Weintraub E et al. Infuenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004).
6. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with infuenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
7. Lee VJ, Yap J, Ong JB et al. Infuenza excess mortality from 1950-2000 in tropical Singapore. PLoS One 4(12), e8096 (2009).
8. Simmerman JM, Chittaganpitch M, Levy J et al. Incidence, seasonality and mortality associated with infuenza pneumonia in Thailand: 2005-2008. PLoS One 4(11), e7776 (2009).
9. Callaghan WM, Chu SY, Jamieson DJ. Deaths from seasonal infuenza among pregnant women in the United States, 1998-2005. Obstet. Gynecol. 115(5), 919-923 (2010).
10. Madjid M, Miller CC, Zarubaev VV et al Infuenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confrmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur. Heart J. 28(10), 1205-1210 (2007).
11. Bhat N, Wright JG, Broder KR et al. Infuenza-associated deaths among children in the United States, 2003-2004. N. Engl. J. Med. 353(24), 2559-2567 (2005).
12. Louie JK, Schechter R, Honarmand S et al Severe pediatric infuenza in California, 2003-2005: implications for immunization recommendations. Pediatrics 117(4), e610-e618 (2006).
13. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffn MR. The effect of infuenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med. 342(4), 225-231 (2000).
14. Izurieta HS, Thompson WW, Kramarz P et al. Infuenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med. 342(4), 232-239 (2000).
15. Chiu SS, Chan KH, Chen H et al Virologically confrmed population-based burden of hospitalization caused by infuenza A and B among children in Hong Kong. Clin. Infect. Dis. 49(7), 1016-1021 (2009).
16. Nicoll A, Ciancio B, Tsolova S, Blank P, Yilmaz C. The scientifc basis for offering seasonal infuenza immunisation to risk groups in Europe. Euro Surveill. 13(43), 19018 (2008).
17. Nokleby H, Nicoll A. Risk groups and other target groups-preliminary ECDC guidance for developing infuenza vaccination recommendations for the season 2010-11. Euro Surveill. 15(12), 19525 (2010).
18. National Advisory Committee on Immunization (NACI). Statement on seasonal trivalent inactivated infuenza vaccine (TIV) for 2009-2010. Canada Communicable Disease Report (CCDR) 35(ACS-6), 1-41 (2009).
19. Belshe RB, Nichol KL, Black SB et al. Safety, effcacy, and effectiveness of live, attenuated, cold-adapted infuenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis. 39(7), 920-927 (2004).
20. Couch RB, Keitel WA, Cate TR. Prevention of infuenza virus infections by current inactivated infuenza vaccines. In: Options for the Control of Infuenza III. Brown LE, Hampson AW, Webster RG (Eds). Elsevier Science, Amsterdam, The Netherlands, 97-106 (1996).
21. Monto AS, Ohmit SE, Petrie JG et al. Comparative effcacy of inactivated and live attenuated infuenza vaccines. N. Engl. J. Med. 361(13), 1260-1267 (2009).
22. Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted infuenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355(24), 2513-2522 (2006).
23. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled Phase 3 trial comparing the immunogenicity of high-dose and standard-dose infuenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200(2), 172-180 (2009).
24. Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of infuenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166(10), 1121-1127 (2006).
25. Podda A. The adjuvanted infuenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17-19), 2673-2680 (2001).
26. Herzog C, Hartmann K, Kunzi V et al. Eleven years of Infexal V-a virosomal adjuvanted infuenza vaccine. Vaccine 27(33), 4381-4387 (2009).
27. de Bruijn I, Meyer I, Gerez L et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional infuenza vaccines in the elderly. Vaccine 26(1), 119-127 (2007).
28. European Medicines Agency. Assessment report for Intanza. EMEA/H/C/000957 (2009).
29. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines 7(8), 1201-1204 (2008).
30. Mikszta JA, Laurent PE. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Rev. Vaccines 7(9), 1329-1339 (2008).
31. Brooks JH, Criep LH, Ruben FL. Intradermal administration of bivalent and monovalent infuenza vaccines. Ann. Allergy 39(2), 110-112 (1977).
32. Francis T Jr, Magill TP. The antibody response of human subjects vaccinated with the virus of human infuenza. J. Exp. Med. 65, 251-259 (1937).
33. Brown H, Kasel JA, Freeman DM et al. The immunizing effect of infuenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J. Infect. Dis. 136(Suppl.), S466-S471 (1977).
34. Belshe RB, Newman FK, Cannon J et al Serum antibody responses after intradermal vaccination against infuenza. N. Engl. J. Med. 351(22), 2286-2294 (2004).
35. Belshe RB, Newman FK, Wilkins K et al Comparative immunogenicity of trivalent infuenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25 (37-38), 6755-6763 (2007).
36. Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of infuenza vaccines. Clin. Vaccine Immunol. 14(4), 375-381 (2007).
37. Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833-8842 (2007).
38. Laurent A, Mistretta F, Bottigioli D et al Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25(34), 6423-6430 (2007).
39. Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal infuenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7, 13 (2009).
40. Leroux-Roels I, Vets E, Freese R et al. Seasonal infuenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 26(51), 6614-6619 (2008).
41. Arnou R, Eavis P, Pardo JR et al. Immunogenicity, large scale safety and lot consistency of an intradermal infuenza vaccine in adults aged 18-60 years: randomized, controlled, Phase III trial. Hum. Vaccin. 6(4), 1-9 (2010).
42. Holland D, Booy R, De Looze F et al. Intradermal infuenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008).
43. Arnou R, Icardi G, De Decker M et al. Intradermal infuenza vaccine for older adults: a randomized controlled multicenter Phase III study. Vaccine 27(52), 7304-7312 (2009).
44. Van Damme P, Arnou R, Kafeja F et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal infuenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis. 10, 134 (2010).
45. Morelon E, Noble CP, Daoud S et al. Immunogenicity and safety of intradermal infuenza vaccination in renal transplant patients who were non-responders to conventional infuenza vaccination. Vaccine 28(42), 6885-6890 (2010).
46. Chevat C, Viala-Danten M, Dias-Barbosa C, Nguyen VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of infuenza vaccination: the Vaccinees' Perception of Injection (VAPI©) questionnaire. Health Qual. Life Outcomes 7, 21 (2009).
47. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal infuenza vaccination: patient reported outcomes from Phase 3 clinical trials. Hum. Vaccin. 6(4) 336-345 (2010).
48. Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59-adjuvanted infuenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17(2), 135-140 (2001).
49. De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted infuenza vaccine in the elderly. Vaccine 17(23-24), 3094-3101 (1999).
50. Keitel WA, Cate TR, Atmar RL et al. Increasing doses of purifed infuenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin. Diagn. Lab. Immunol. 3(5), 507-510 (1996).
51. Ansaldi F, Bacilieri S, Durando P et al. Cross-protection by MF59-adjuvanted infuenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted infuenza viruses. Vaccine 26(12), 1525-1529 (2008).
52. Keitel WA, Atmar RL, Nino D, Cate TR, Couch RB. Increasing doses of an inactivated infuenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J. Infect. Dis. 198(7), 1016-1018 (2008).
53. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197-3208 (2008).
54. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M et al. Safety and effcacy of a novel microneedle device for dose sparing intradermal infuenza vaccination in healthy adults. Vaccine 27(3), 454-459 (2009).
55. Sullivan SP, Koutsonanos DG, Del Pilar MM et al. Dissolving polymer microneedle patches for infuenza vaccination. Nat. Med. 16(8), 915-920 (2010).
56. Du L, Zhou Y, Jiang S. Research and development of universal infuenza vaccines. Microbes Infect. 12(4), 280-286 (2010).
57. Herzog C, Hartmann K, Kunzi V et al. Eleven years of Infexal V-a virosomal adjuvanted infuenza vaccine. Vaccine 27(33), 4381-4387 (2009).
58. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for infuenza vaccines. CPMP/BWP/214/96, 1-18 (1997).